drugset

drugset / Trial / NCT00869895

A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors

NCT00869895 ↗

Phase 1 Completed 60 enrolled Eisai Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of E7050 given orally in patients with advanced solid tumors.

Timeline

Start: 2009-03
Primary completion: 2012-08
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Golvatinib	Small molecule	100 mg	Oral

Indications